United Therapeutics Files 8-K Report
Ticker: UTHR · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1082554
| Field | Detail |
|---|---|
| Company | United Therapeutics Corp (UTHR) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
Related Tickers: UNTH
TL;DR
UNTH filed an 8-K, mostly routine stuff, no major news yet.
AI Summary
On September 2, 2025, United Therapeutics Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific material events detailed in the provided text. The company, incorporated in Delaware, is based in Silver Spring, MD, and operates in the Pharmaceutical Preparations industry.
Why It Matters
This 8-K filing indicates routine corporate reporting by United Therapeutics Corporation, providing updates on their regulatory filings and financial statements.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any immediate material risks or significant events.
Key Numbers
- 000-26301 — SEC File Number (Identifies the company's filing history with the SEC.)
- 52-1984749 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- United Therapeutics Corporation (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Silver Spring, MD (location) — Principal Executive Offices
- September 2, 2025 (date) — Date of earliest event reported
FAQ
What specific "Other Events" are being reported by United Therapeutics Corporation in this 8-K filing?
The provided text does not detail the specific "Other Events" being reported, only that this item is included in the filing.
What is the significance of the "Financial Statements and Exhibits" being filed?
This indicates that updated financial information or related documents are being submitted to the SEC, though the specifics are not in the provided excerpt.
When was United Therapeutics Corporation incorporated, and where are its principal executive offices located?
United Therapeutics Corporation was incorporated in Delaware and its principal executive offices are located at 1000 Spring Street, Silver Spring, MD 20910.
What is the SIC code for United Therapeutics Corporation, and what industry does it represent?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the date of the earliest event reported in this Form 8-K?
The date of the earliest event reported is September 2, 2025.
Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-09-02 07:00:49
Key Financial Figures
- $0.01 — h registered Common Stock, par value $0.01 per share UTHR Nasdaq Global Select
Filing Documents
- tm2524831d1_8k.htm (8-K) — 27KB
- tm2524831d1_ex99-1.htm (EX-99.1) — 29KB
- tm2524831d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-25-085976.txt ( ) — 229KB
- uthr-20250902.xsd (EX-101.SCH) — 3KB
- uthr-20250902_lab.xml (EX-101.LAB) — 33KB
- uthr-20250902_pre.xml (EX-101.PRE) — 22KB
- tm2524831d1_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On September 2, 2025, United Therapeutics Corporation issued a press release announcing positive results of the TETON-2 clinical study of Tyvaso (treprostinil) Inhalation Solution in patients with idiopathic pulmonary fibrosis. The press release is attached as Exhibits 99.1 and is incorporated herein by reference. TYVASO is a registered trademark of United Therapeutics Corporation.
01. Exhibits
Item 9.01. Exhibits (d) Exhibits Exhibit No. Description of Exhibit 99.1 Press release dated September 2, 2025 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. UNITED THERAPEUTICS CORPORATION Dated: September 2, 2025 By: /s/ Paul A. Mahon Name: Paul A. Mahon Title: General Counsel 3